Paracetamol remains one of the drugs most frequently implicated in deliberate self‐poisoning overdoses in Australia
Paracetamol is the pharmaceutical agent most frequently taken for deliberate self‐poisoning by adults and adolescents in Australia, the United Kingdom, and other developed countries.1 It is primarily taken in overdose by younger women, in most cases for deliberate self‐harm. Toxicity can also result from accidental repeated supra‐therapeutic ingestion, particularly by people at higher risk of hepatotoxicity.2
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Buckley N, Eddleston M. Paracetamol (acetaminophen) poisoning. BMJ Clin Evid 2007; 2007: 2101.
- 2. Alhelail MA, Hoppe JA, Rhyee SH, Heard KJ. Clinical course of repeated supratherapeutic ingestion of acetaminophen. Clin Toxicol (Phila) 2011; 49: 108–112.
- 3. Cairns R, Brown JA, Wylie CE, et al. Paracetamol poisoning‐related hospital admissions and deaths in Australia, 2004–2017. Med J Aust 2019; 211: 218–223.
- 4. Hawton K, Bergen H, Simkin S, et al. Impact of different pack sizes of paracetamol in the United Kingdom and Ireland on intentional overdoses: a comparative study. BMC Public Health 2011; 11: 460.
- 5. Bateman DN, Gorman DR, Bain M, et al. Legislation restricting paracetamol sales and patterns of self‐harm and death from paracetamol‐containing preparations in Scotland. Br J Clin Pharmacol 2006; 62: 573–581.
- 6. Hawton K, Bergen H, Simkin S, et al. Long‐term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ 2013; 346: f403.
- 7. Chiew AL, Isbister GK, Page CB, et al. Modified release paracetamol overdose: a prospective observational study (ATOM‐3). Clin Toxicol (Phila) 2018; 56: 810–819.
- 8. Chiew AL, Fountain JS, Graudins A, et al. Summary statement: new guidelines for the management of paracetamol poisoning in Australia and New Zealand. Med J Aust 2015; 203: 215–218. https://www.mja.com.au/journal/2015/203/5/summary-statement-new-guidelines-management-paracetamol-poisoning-australia-and
- 9. Therapeutic Goods Administration. Interim decisions and invitation for further comment on substances referred to the March 2019 ACMS/ACCS meetings. 6 June 2019. https://www.tga.gov.au/book-page/15-interim-decision-relation-paracetamol-modified-release (viewed July 2019).
- 10. European Medicines Agency. Modified‐release paracetamol‐containing products to be suspended from EU market [EMA/118413/2018]. 19 Feb 2018. https://www.ema.europa.eu/medicines/human/referrals/paracetamol-modified-release (viewed Nov 2018).
- 11. Sandilands EA, Bateman DN. Adverse reactions associated with acetylcysteine. Clin Toxicol (Phila) 2009; 47: 81–88.
- 12. Wong A, Graudins A. Simplification of the standard three‐bag intravenous acetylcysteine regimen for paracetamol poisoning results in a lower incidence of adverse drug reactions. Clin Toxicol (Phila) 2016; 54: 115–119.
- 13. Chiew AL, Isbister GK, Kirby KA, et al. Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM‐2). Clin Toxicol (Phila) 2017; 55: 1055–1065.
- 14. Wong A, McNulty R, Taylor D, et al. The NACSTOP trial: a multicenter, cluster‐controlled trial of early cessation of acetylcysteine in acetaminophen overdose. Hepatology 2019; 69: 774–784.
No relevant disclosures.